A NSW Government website


Chemical Pathology Research

Chemical pathology is devoted to the measurement of the chemicals, hormones and metabolites that make life possible. Pathology is responsible for the study of all forms of disease, so the activities of our department are extremely broad and diverse. Our research encompasses many disorders which can be classified in terms of the organs or age-groups that they affect, but there is an understandable emphasis on those conditions that cause the greatest amount of death and disability in Australia at the moment.

Our Key Achievements

  • Our department has led the implementation of strategies to address the most common potentially fatal genetic disorder, Familial Hypercholesterolaemia.
  • Our department has led the implementation strategies to manage the first new independent risk factor for atherosclerotic CVD discovered this century, lipoproptein (a).
  • Our department is at the forefront of innovations in personalized medicine involving trials of small interfering RNA therapies. These are based on Mendelian Randomization studies which have identified ANGPTL3, APO C3 and APO (a) as therapeutic targets. This will reduce the risk of CVD and acute pancreatitis in selected patients.

Our Research Team

Kerry Kearins Clinical Trial Coordinator
Collin Tran Research Scientist

Our Publications


Bulsara C, Brett T, Radford J, et al. Awareness of familial hypercholesterolaemia in Australian primary care: A qualitative descriptive study. Australian journal of general practice 2021;50:634-40.
Clifton P, Sullivan D, Baker J, et al. ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia. Circulation 2021;144:A10357-A.
Januszewski AS, Chen D, Scott RS, et al. Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific reports 2021;11:1-12.
Lin H-M, Mak B, Yeung N, et al. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine 2021;72:103625.
Nestel PJ, Sullivan DR, Mori TA. Dietary management of cardiovascular risk including type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 2021;28:134-41.
Ong K-L, Wu L, Januszewski AS, et al. The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diabetes and Vascular Disease Research 2021;18:14791641211032547.
Pang J, Sullivan DR, Hare DL, et al. Gaps in the care of familial hypercholesterolaemia in Australia: first report from the National registry. Heart, Lung and Circulation 2021;30:372-9.
Spinks C, Watts GF, Pang J, Brett T, Sullivan DR. Genetic testing for familial hypercholesterolaemia: A test for the family. Medicine Today 2021;22.
Watts GF, Sullivan DR, Hare DL, et al. Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. Internal medicine journal 2021;51:769-79.
Watts GF, Sullivan DR, Hare DL, et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart, Lung and Circulation 2021;30:324-49.
Watts GF, Sullivan DR, Hare DL, et al. Synopsis of an Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia: an Australian Perspective. American Journal of Preventive Cardiology 2021:100151.
Zhen XM, Lee KL, Sullivan D, Acharya S. New diagnosis of diabetes and severe hyperlipidemia at 3 months postpartum presenting as florid diabetic retinopathy and eruptive xanthomas. Journal of Obstetrics and Gynaecology Research 2021;Published ahead of print.